Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 10/20 | 0.48 |
| ▸ | PPARA | Q07869 | 6/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2939051 | 1.00 | CYP2C9 (0.51) | CYP2C9CYP1A2GAAPKMCYP2C19 | |
| SCHEMBL15672572 | 0.87 | TDP1 (0.51) | CYP2C9CYP1A2GAAPKMCYP2C19 | |
| SCHEMBL15672574 | 0.87 | TDP1 (0.51) | CYP2C9CYP1A2GAAPKMCYP2C19 | |
| SCHEMBL7471783 | 0.87 | TDP1 (0.51) | CYP2C9CYP1A2GAAPKMCYP2C19 | |
| SCHEMBL1125437 | 0.85 | CYP2C9 (0.50) | CYP2C9CYP1A2GAAPKMCYP2C19 | |
| SCHEMBL11542319 | 0.85 | CYP2C9 (0.50) | CYP2C9CYP1A2GAAPKMCYP2C19 | |
| SCHEMBL3921799 | 0.85 | CYP2C9 (0.50) | CYP2C9CYP1A2GAAPKMCYP2C19 | |
| SCHEMBL8694692 | 0.85 | CYP2C9 (0.50) | CYP2C9CYP1A2GAAPKMCYP2C19 | |
| SCHEMBL11814155 | 0.85 | CYP2C9 (0.50) | CYP2C9CYP1A2GAAPKMCYP2C19 | |
| SCHEMBL3165356 | 0.84 | PTGDR2 (0.56) | CYP2C9CYP1A2GAAPKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050446-B1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2050446-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | PTGER1, CYSLTR1, PTGER2 | CYP2C9 3311/4885CYP1A2 2864/4885GAA 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.